Influenza Vaccine Clinical Trial
Official title:
A Randomized, Controlled Trial Comparing Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients
Verified date | May 2015 |
Source | University of Alberta |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
The influenza virus, commonly called the flu, is a common source of infection in lung transplant patients and can often lead to pneumonia and possibly rejection. The annual influenza vaccine is the most important strategy used to prevent infection but it is not effective in all lung transplant patients. It has been thought that the response to the vaccine may be improved if it is given into the skin (intradermal) rather than the muscle (intramuscular). We hypothesize that a significantly greater proportion of patients will respond to vaccination using the intradermal influenza vaccine compared to the intramuscular vaccine.
Status | Completed |
Enrollment | 85 |
Est. completion date | February 2010 |
Est. primary completion date | December 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Age = 18 - Greater than 3 months post-transplant - Outpatient status Exclusion Criteria: - Has already received influenza vaccination for 2008-2009 season - Egg allergy - Previous life-threatening reaction to influenza vaccine (i.e. Guillain Barre Syndrome) - On anticoagulants such as warfarin that precludes intramuscular injection - Ongoing therapy for rejection - Febrile illness in the past two weeks - Unable to provide informed consent - Unable to comply with study protocol |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Canada | University of Alberta Hospital | Edmonton | Alberta |
Switzerland | University Hospital of Lausanne | Lausanne |
Lead Sponsor | Collaborator |
---|---|
University of Alberta | University of Lausanne Hospitals |
Canada, Switzerland,
Manuel O, Humar A, Chen MH, Chernenko S, Singer LG, Cobos I, Kumar D. Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant. 2007 Nov;7(11):2567-72. Epub 2007 Oct 1. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Seroconversion rate: serological response with a four-fold or greater increase in HI antibody titers Seroprotection rate: HIA titers of >/= 1:40 | 4 weeks | Yes | |
Secondary | Local and systemic adverse events to vaccination | 24 hours, 48 hours and 7 days after each vaccination | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03285997 -
A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age
|
Phase 3 | |
Recruiting |
NCT05996549 -
Cost-effectiveness of the Influenza Vaccination
|
Phase 4 | |
Completed |
NCT04546854 -
Influenza 2020/2021
|
N/A | |
Completed |
NCT05157425 -
Effect of a Multi-strain Probiotic Formulation on Immune Response to Influenza Vaccination
|
N/A | |
Completed |
NCT01687517 -
Efficacy and Safety of Influenza Vaccine During Sarcoidosis
|
Phase 3 | |
Completed |
NCT01180699 -
Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients
|
N/A | |
Completed |
NCT00542776 -
Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine
|
N/A | |
Completed |
NCT06304038 -
Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome
|
||
Recruiting |
NCT04086628 -
Influenza Vaccine in Children With Asthma
|
||
Completed |
NCT02960815 -
Imiquimod and Influenza Vaccine for Immunocompromised Patients
|
Phase 2 | |
Completed |
NCT00828555 -
Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting
|
N/A | |
Completed |
NCT04230343 -
Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour
|
N/A | |
Recruiting |
NCT03399357 -
Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial
|
N/A | |
Completed |
NCT02153671 -
Immunogenicity of H5N1 Vaccine Following H5N2
|
Phase 2 | |
Completed |
NCT00461981 -
A Phase 2 Study to Evaluate Immune Responses of FluMist®
|
Phase 2 | |
Recruiting |
NCT05070494 -
Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT04785794 -
Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old
|
Phase 1 | |
Completed |
NCT05163847 -
Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults
|
Phase 1 | |
Not yet recruiting |
NCT04355806 -
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
|
||
Completed |
NCT01368796 -
Comparison of 4 Influenza Vaccines in Seniors
|
Phase 4 |